AbbVie (ABBV) Stock – Latest Investor Update

Shares of Health Care sector company AbbVie moved -1.0% today, and are now trading at a price of $170.39. The Large-Cap stock's daily volume was 12,308,051 compared to its average volume of 5,292,501. The S&P 500 index returned a -0.0% performance.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company is based in North Chicago and has 50,000 full time employees. Its market capitalization is $300,886,589,440. AbbVie currently offers its equity investors a dividend that yields 3.5% per year.

25 analysts are following AbbVie and have set target prices ranging from $170.0 to $207.0 per share. On average, they have given the company a rating of buy. At today's prices, ABBV is trading -7.44% away from its average analyst target price of $184.08 per share.

Over the last year, ABBV's share price has increased by 26.3%, which represents a difference of 0.0% when compared to the S&P 500. The stock's 52 week high is $182.89 per share whereas its 52 week low is $130.96. With average free cash flows of $18.44 Billion that have been growing at an average rate of 11.5% over the last 5 years, AbbVie is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 22,839,000 777,000 22,062,000 -9.02
2022 24,943,000 695,000 24,248,000 10.27
2021 22,777,000 787,000 21,990,000 30.97
2020 17,588,000 798,000 16,790,000 31.46
2019 13,324,000 552,000 12,772,000 -0.13
2018 13,427,000 638,000 12,789,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.